Full Press Release Details
Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG
January 31, 2024 - FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused
on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced
that trading of the FibroBiologics stock commenced today on Nasdaq under the stock ticker FBLG.
statement was made in connection with FibroBiologics' registration statement on Form S-1 (File No.: 333-275361) filed with the
U.S. Securities and Exchange Commission (SEC) on November 7, 2023. The registration statement was declared effective on January 24, 2024.
Statement Regarding Forward-Looking Statements
communication may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include information concerning FibroBiologics' possible or assumed future results of operations, business
strategies, debt levels, competitive position, industry environment, potential growth opportunities and the effects of regulation, including
whether FibroBiologics will generate returns for stockholders. These forward-looking statements are based on FibroBiologics' management's
current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. When used in this
communication, the words "estimates," "projected," "expects," "anticipates," "forecasts,"
"plans," "intends," "believes," "seeks," "may," "will," "should,"
"future," "propose" and variations of these words or similar expressions (or the negative versions of such words
or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance,
conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many
of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the
results discussed in the forward-looking statements, including those set forth in the Risk Factors section of FibroBiologics' Registration
Statement for the Direct Offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties,
assumptions and other important factors include, but are not limited to: (a) the occurrence of any event, change or other circumstances
that could cause the Registration Statement to not become effective; (b) the ability of FibroBiologics to continue to meet Nasdaq listing
requirements; (c) the ability to effectively manage the business as a result of the super-voting proxy given to the Board of Directors.
Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking
statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking
statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve
in Houston, FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for
chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents
pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ
involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit
Johnson or Harrison Seidner, Ph.D.